A typical compounded semaglutide dosage chart for weight loss is included below
This is always a clinical decision, but some patterns have emerged in the way providers describe their prescribing preferences: Tirzepatide tends to be preferred for patients seeking maximum weight loss, patients with type 2 diabetes (where the dual mechanism helps glycemic control), and patients who have not responded adequately to semaglutide
Second, this study did not consider discontinuation, although in another study, Truveta explored factors associated with GLP-1 RA discontinuation and reinitiation including but not limited to weight loss/gain, adverse side-effects, comorbidities, and sociodemographic characteristics
This immune reprogramming occurs through the GLP-1R/PPARG/ACSL1 signaling pathway
Code availability Code for the analysis is publicly available and available without restriction via GitHub at References Phelps, N